ReviewIndian journal of ophthalmology2026
Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macular edema is the leading cause of visual impairment in retinal vein occlusion (RVO). Management has evolved significantly with advances in retinal imaging and the recognition of vascular endothelial growth factor (VEGF) as a key pathogenic mediator. Anti-VEGF agents are now the mainstay of treatment, supported by robust evidence from randomized clinical trials and real-world studies. Intravitreal corticosteroids play a selective role in patients with suboptimal anti-VEGF responses or contraindications to anti-VEGFs, while the role of laser photocoagulation has become limited. Optical coherence tomography remains central to diagnosis, monitoring, and prognostication. Fluorescein angiography and optical coherence tomography have a role in assessing retinal perfusion, including the macula. Emerging therapies, including biosimilars and long-acting delivery systems, aim to increase accessibility and durability of treatment in RVO-related macular edema (RVO-ME). This review summarizes current evidence and future directions in the management of RVO-ME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.